Full Breakdown
Compassionate Use of Eli Lilly’s Retatrutide for an Unnamed 79-Year-Old Patient
6/23/2026, 9:27:20 PM
Core Event: FDA Grants Compassionate Use for Experimental Obesity Drug
In April 2026 the FDA approved a compassionate-use request that let a 79-year-old man receive retatrutide, Eli Lilly’s experimental obesity drug. The request was filed by NIH senior clinician Ranganath Muniyappa for refractory obesity with obstructive sleep apnea and pulmonary hypertension. Sources say the patient’s identity was not disclosed but that the application attracted senior health officials’ attention.
Background & Context: Retatrutide and the Compassionate-Use Pathway
Retatrutide has produced weight-loss results comparable to bariatric surgery in early trials, sparking public interest. The FDA’s compassionate-use program permits limited access to investigational drugs for patients with serious, life-threatening conditions lacking approved therapies.
Key Figures & Organizations
Eli Lilly developed retatrutide. The FDA granted the compassionate-use exemption. Ranganath Muniyappa of the NIH submitted the request. White House spokesperson Kush Desai referred the inquiry to the Department of Health and Human Services, whose spokesperson Emily Hilliard declined comment. Former President Donald Trump’s health has been publicly discussed, but his identity has not been confirmed as the patient.
Timeline of the Compassionate-Use Request
- April 2026 – Muniyappa files the request.
- May 2026 – STAT reporter Lizzy Lawrence contacts the White House.
- June 2026 – White House spokesperson Kush Desai redirects the query to HHS; HHS provides no comment.
- June 23 2026 – Media outlets report the case and note speculation that the patient could be Donald Trump.
Official Statements & Responses
The White House said a recent medical memo “covers this” request but did not mention obstructive sleep apnea or pulmonary hypertension. HHS declined to address the compassionate-use application or the patient’s identity.
Criticism, Opposition, and Public Speculation
Social-media users framed the exemption as preferential treatment for a well-connected individual. Bluesky user Michah asked, “I mean this couldn’t possibly be anyone else, right?” HuffPost’s Paul Blumenthal responded, “Compassionate use you say.” Lawfare’s Eric Columbus highlighted the White House’s silence.
Conflicting Reports & Gaps
Neither the White House nor HHS confirmed the patient’s identity, and the memo cited by Desai omits the specific conditions listed in the request. Consequently, the possibility that the individual is former President Donald Trump remains unverified.
Verbatim Quotes
- “Sources told STAT that application drew interest from top health officials,” — Lizzy Lawrence, STAT reporter
- “In response to STAT’s question about whether Trump has obstructive sleep apnea and pulmonary hypertension, Desai said a White House memo detailing Trump’s most recent medical evaluation 'covers this.' The memo makes no mention of obstructive sleep apnea or pulmonary hypertension.” — Kush Desai, White House spokesperson
- “I mean this couldn’t possible be anyone else, right?” — Michah, Bluesky user
- “compassionate use” — Paul Blumenthal, HuffPost
What’s Next
The FDA has not signaled whether further compassionate-use requests for retatrutide will be approved. Ongoing media attention may prompt additional clarification from the White House or HHS about the patient’s identity and the criteria used.
